Cisplatin-based chemotherapy in advanced seminoma: Experience of the Northern Israel Oncology Center: 1981–1994

Stein, Moshe; Kuten, Abraham; Drumea, Keren; Moshkowitz, B.; Nativ, Ofer; Munichor, Mariane; Haim, Nissim

doi:10.1002/(sici)1096-9098(199704)64:4<331::aid-jso15>3.0.co;2-5

Cited by 2 publications

(2 citation statements)

References 22 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our long-term results, comparing to other studies,4,5 show that AS is highly sensitive to platinum-based chemotherapy, with up to 85%–100% of patients showing durable complete remission1,5 and survival rates greater than 90% in 10 years 1,6. Toxicity was mild and manageable in most of the studies, apart from reports of late second primaries, either solid or hematological in nature7–9 which can be a real challenge in cured patients.…”

Section: Discussionsupporting

confidence: 54%

“…About 80% of patients with advanced seminoma (AS) (bulky adenopathy, stage IIC; or mediastinal/supraclavicular, stage IIIA) presentation can achieve a durable complete response and long-term disease-free survival following cisplatin-based chemotherapy 1,2. In recent years, cisplatin-based chemotherapy has replaced radiotherapy as the standard treatment for patients with AS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Platinum-based Chemotherapy in Primary Advanced Seminoma—a Retrospective Analysis: Treatment Results at the Northern Israel Oncology Center (1989-2010)

Stein¹,

Drumea²,

Charas³

et al. 2014

RMMJ

Self Cite

View full text Add to dashboard Cite

Objective:Over the past 30 years, great strides have been made in the treatment of disseminated testicular tumors. Despite the low number of patients and the rarity of studies concerning primary advanced seminoma, the efficacy of chemotherapy is clear, mainly 3–4-cisplatin-based chemotherapy. Aiming to contribute to the understanding and implementation of proper chemotherapeutic management in advanced seminoma patients, we retrospectively summarized our experience with 26 patients who were referred for platinum-based chemotherapy, post-orchiectomy to the Northern Israel Oncology Center between 1989 and 2010. Response rate, side effects, and long-term outcome were investigated.Methods:Before chemotherapy, meticulous staging was done, including tumor markers (B-human chorionic gonadotropin (B-HCG), alpha-fetoprotein (AFP), and lactic dehydrogenase (LDH)), and abdominal and pelvic computerized tomography (CT) scans were carried out.Results:All 26 treated patients achieved complete remission, clinically and symptomatically, with normalization of their CT scans. At a median follow-up of 120 months (range, 24–268 months) all patients are alive, without evidence of recurrent disease. One patient whose disease recurred twice achieved a third complete remission following salvage treatment with high-dose chemotherapy and autologous peripheral stem cell transplantation. Another patient, who preferred surveillance, relapsed abdominally after 9 months but achieved long-standing complete remission with cisplatin-based chemotherapy. Both these patients are alive with no evidence of disease. Three patients recovered uneventfully from bleomycin-induced pneumonitis.Conclusions:Advanced seminoma is a highly curable disease using platinum-based chemotherapy. Our study confirms the efficacy and safety of cisplatin-based chemotherapy in the treatment of advanced seminoma.

show abstract